Funding the future of retinal health with Eyepoint

What It Covers

EyePoint Pharmaceuticals CFO George Elston outlines the company's DuraView program for wet AMD, its $318M cash runway through 2027, two global Phase 3 trials, and capital allocation strategy at RBC's 2025 Global Healthcare Conference.

Key Questions Answered

• •DuraView Mechanism Differentiation: DuraView (vorolanib) introduces the first new mechanism of action in retinal disease in 15–20 years. Unlike anti-VEGF biologics lasting ~28 days, its DuraSert E insert delivers zero-order kinetics for six continuous months, positioning it as a complementary maintenance therapy rather than a replacement.
• •Phase 3 Trial Milestones: EyePoint is running two global Phase 3 trials — Lugano (over 90% enrolled) and Lucia (over 50% enrolled) — with enrollment completion expected in 2025 and top-line data readout in 2026, funded through 2027 on $318M in cash as of March 2025.
• •Commercial Launch Strategy: EyePoint plans a self-funded U.S. launch requiring approximately 70 sales reps to reach roughly 2,400 U.S. retinal specialists. Outside the U.S., the company actively seeks a global commercial partner, given substantially different treatment dynamics in international markets.
• •Biotech CFO Cash Management: Elston advises biopharma financial executives to prioritize clinical trial spending over overhead like office leases and furniture, maintain strict burn control, and raise capital proactively. Phase 2 DME data in 2024 enabled EyePoint to secure its current multi-year runway before market conditions deteriorated.